Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

1. Grisham, R.N.
2. Vergote, I.
3. Banerjee, S.
4. Drill, E.
5. Kalbacher, E.
6. Mirza, M.R.
7. Romero, I.
8. Vuylsteke, P.
9. Coleman, R.L.
10. Hilpert, F.
11. Oza, A.M.
12. Westermann, A.
13. Oehler, M.K.
14. Pignata, S.
15. Aghajanian, C.
16. Colombo, N.
17. Cibula, D.
18. Moore, K.N.
19. del Campo, J.M.
20. Berger, R.
21. Marth, C.
22. Sehouli, J.
23. O’Malley, D.M.
24. Churruca, C.
25. Kristensen, G.
26. Clamp, A.
27. Farley, J.
28. Iyer, G.
29. Ray-Coquard, I.
30. Monk, B.J.
31. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1158/1078-0432.CCR-23-0621 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus